Key facts
- This page summarizes Urte Gayko's Form 4 filing for Summit Therapeutics Inc. (SMMT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Apr 2022, 16:36.
Urte Gayko - 25 Apr 2022 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)
- Reporting relationship
- Director
- Issuer ticker
- SMMT
- Reported as of
- 25 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Apr 2022, 16:36:58 UTC
- Prior SEC filing
- 05 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Urte Gayko
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Urte Gayko filed Form 4 for Summit Therapeutics Inc. (SMMT) on 26 Apr 2022.
Change
- Previous filing in this sequence was filed on 05 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SMMT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +400,000
- Change %
- Price
- Shares after
- 400,000
- Date
- 25 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,000
- Exercise price
- $1.93
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option was granted on April 25, 2022. The shares underlying the option are scheduled to vest in four equal annual installments over four years.
Footnote F2
Not applicable.